Biospecimen Core for HMCA Development
Official title: Biospecimen Core supporting the preclinical and clinical development of highly multivalent contraceptive antibody (HMCA)
Funded at Mucommune, LLC · NIH-11464359 · Data updated 2026-11-12
A team at Mucommune is building a specialized lab core to measure HMCA antibody levels precisely in animals and people to guide dosing and safety in non-hormonal contraceptive development.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mucommune, LLC NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | September 7, 2026 |
| Project end | August 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $95,436 |
| NIH project number | 1P50HD123737-01 |
| Project ID | NIH-11464359 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals participating in related HMCA clinical trials or future patients who would contribute biological samples for pharmacokinetic analyses.
✕Less likely to help
Participants not providing relevant samples or not enrolled in HMCA clinical studies may not directly benefit.
What this research studies
This grant funds a biospecimen core that uses ELISA to quantify HMCA concentrations in various biological fluids, including serum and mucus, across preclinical and clinical stages. The goal is to provide accurate drug exposure data to inform human dosing, pharmacodynamics, and safety, and to support regulatory filings for late-stage development. The work relies on validated antibody-based assays and leverages prior experience with different species to ensure reliable measurements in diverse matrices.
Why it matters
Potential benefit: If successful, the project could improve dosing accuracy and safety monitoring for HMCA-based contraception.
How similar studies have gone: ELISA-based quantitation of monoclonal antibodies in humans and animals has a strong track record for guiding clinical development.
Where this research is happening
-
Mucommune, LLC
Morrisville, United States Active
Researchers
- Principal investigator: Scott, David W — Mucommune, LLC
- Study coordinator: Scott, David W
Related research
Other NIH-funded projects on the same topics.
-
Long‑lasting antibody vaginal ring for non‑hormonal birth control
Testing a vaginal ring that slowly releases an antibody to trap sperm and prevent pregnancy for people seeking non‑hormonal contraception.
-
Vaginal ring releasing non-hormonal antibody contraception for month-long use
A monthly vaginal ring delivers a non-hormonal antibody-based contraceptive, offering a convenient, user-controlled option for women who want to avoid daily dosing or invasive procedures.
-
On-demand non-hormonal vaginal contraception with a fast-dissolving antibody tablet
A new on-demand vaginal tablet dissolves quickly to release a monoclonal antibody for non-hormonal contraception.
-
Non-hormonal contraceptive antibodies for on-demand vaginal tablet and monthly ring options
A patient-friendly opportunity to support development of a non-hormonal birth control method using a vaginal tablet or ring powered by a potent antibody.
-
Non-hormonal, antibody-based contraception that can be used on demand or long-acting
A new antibody-based method aims to provide safe, hormone-free birth control that a person can use when they choose, with options for both quick-use and longer-lasting protection.
-
In vivo B7-H3 CAR-T cells for pancreatic cancer therapy
A patient-friendly look at a new approach that aims to produce CAR-T cells directly inside the body to target pancreatic cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.